Expert Review of Anticancer Therapy最新文献_第3页

Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges. 目前正在研究的雄激素受体拮抗剂治疗耐药前列腺癌：进展和挑战。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-03-20 DOI: 10.1080/14737140.2025.2481141

Linda Danielli, Elisa Tassinari, Andrea Marchetti, Matteo Rosellini, Veronica Mollica, Liang Cheng, Francesco Massari

{"title":"Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges.","authors":"Linda Danielli, Elisa Tassinari, Andrea Marchetti, Matteo Rosellini, Veronica Mollica, Liang Cheng, Francesco Massari","doi":"10.1080/14737140.2025.2481141","DOIUrl":"10.1080/14737140.2025.2481141","url":null,"abstract":"Introduction: Prostate cancer represents a significant oncological challenge, with its natural history predominantly driven by androgen receptor (AR) signaling. The pivotal role of this pathway underscores the rationale for targeting AR activity in therapeutic strategies. However, the development of resistance mechanisms has highlighted the need for advanced therapies to address the complexity of the castration-resistant status.Areas covered: We analyzed the evolving role of second-generation androgen receptor signaling inhibitors (ARSIs) in the management of non-metastatic and metastatic castration-resistant prostate cancer, we critically examine emerging combination strategies involving ARSIs, novel agents targeting resistance pathways, and the mechanisms underlying treatment resistance. The review also provides insights into future directions for enhancing outcomes. PubMed literature research using keywords related to castration-resistant prostate cancer and its treatments was performed, including the most relevant trials and reviews.Expert opinion: ARSIs have revolutionized the management of prostate cancer, providing substantial clinical benefits and representing the cornerstone of current treatment paradigms. However, key challenges remain, including determining optimal treatment sequencing, overcoming resistance mechanisms, and tailoring therapies to specific molecular subtypes. Biomarker-driven approaches are critical for refining patient selection and improving therapeutic outcomes. Ongoing trials investigating novel hormonal-axis-directed agents and innovative combination therapies aim to expand the arsenal of effective treatment.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.9,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A nuanced review of neoadjuvant therapies in oral cancer. 口腔癌新辅助治疗的细致回顾。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-03-19 DOI: 10.1080/14737140.2025.2478891

Akshat Malik, Kanishk Vishnoi, Vanita Noronha, Kumar Prabhash

引用次数: 0

Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors. 口服选择性雌激素受体降解物（SERDs）在激素受体阳性her2阴性转移性乳腺癌进展后使用CDK4/6抑制剂。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-03-15 DOI: 10.1080/14737140.2025.2479604

Taha Koray Sahin, Sercan Aksoy, Deniz Can Guven

{"title":"Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors.","authors":"Taha Koray Sahin, Sercan Aksoy, Deniz Can Guven","doi":"10.1080/14737140.2025.2479604","DOIUrl":"10.1080/14737140.2025.2479604","url":null,"abstract":"Introduction: Hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC) remains a prevalent and challenging disease. Endocrine therapy (ET) combined with CDK4/6 inhibitors is the first-line standard of care, yet resistance mechanisms, including ESR1 mutations, drive disease progression. Novel oral selective estrogen receptor degraders (SERDs) have emerged as promising therapeutic agents after progression with CDK4/6 inhibitors secondary to ESR1 mutations. However, the available studies on SERDs differ in design, study population, and outcomes, necessitating a critical review of available data.Areas covered: This review explores the mechanisms, clinical efficacy, and safety profiles of oral SERDs in HR-positive, HER2-negative mBC, particularly following progression on CDK4/6 inhibitors. Recent key clinical trials, including EMERALD, SERENA-2, EMBER-3 and AMEERA-3, are analyzed, highlighting their efficacy in overcoming resistance, especially in ESR1-mutant populations.Expert opinion: Oral SERDs offer enhanced bioavailability and convenience compared to fulvestrant, representing a critical advancement in endocrine therapy. Their integration into treatment strategies, particularly in combination regimens and ctDNA-driven approaches, may improve patient outcomes and address resistance mechanisms. However, other than ESR1 mutations, clinical refinement for patient selection is limited. Further trials are needed to optimize patient selection for oral SERD use and define the most effective combination strategies with oral SERDs.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.9,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persisting challenges in the early detection of hepatocellular carcinoma. 肝细胞癌早期发现的持续挑战。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-24 DOI: 10.1080/14737140.2025.2467184

Ashwini Arvind, Kennedy Redmon, Amit G Singal

{"title":"Persisting challenges in the early detection of hepatocellular carcinoma.","authors":"Ashwini Arvind, Kennedy Redmon, Amit G Singal","doi":"10.1080/14737140.2025.2467184","DOIUrl":"10.1080/14737140.2025.2467184","url":null,"abstract":"Introduction: Prognosis in patients with HCC is largely determined by stage at diagnosis, highlighting the importance of effective early detection strategies. HCC surveillance is associated with increased early detection and reduced HCC-related mortality and is currently recommended in patients with cirrhosis or chronic HBV infection.Areas covered: We performed a targeted literature review to identify limitations of current HCC surveillance practices and strategies for improvement.Expert opinion: Semi-annual ultrasound continues as the cornerstone modality for HCC surveillance but has limited sensitivity for detecting early-stage HCC, particularly in patients with obesity and non-viral etiologies. Although sensitivity for early-stage HCC can be improved by using ultrasound with alpha fetoprotein, this strategy misses over one-third of HCC at an early stage. Emerging imaging and biomarker-based surveillance strategies currently remain in varying stages of validation and are not yet ready for routine use in practice. The cost-effectiveness of surveillance in patients with non-cirrhotic liver disease related to hepatitis C or metabolic dysfunction-associated steatotic liver disease continues to be debated, although subgroups with advanced fibrosis may warrant surveillance. Finally, the effectiveness of surveillance is diminished by underuse in clinical practice, particularly in racial minority and low-income groups, highlighting a need for interventions to increase utilization.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of machine learning prognostic models for overall survival of epithelial ovarian cancer patients: a SEER-based study. 开发用于上皮性卵巢癌患者总体生存的机器学习预后模型：一项基于预言家的研究。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-16 DOI: 10.1080/14737140.2025.2465903

Jianing Fan, Yu Jiang, Xinyan Wang, Juan Lyv

{"title":"Development of machine learning prognostic models for overall survival of epithelial ovarian cancer patients: a SEER-based study.","authors":"Jianing Fan, Yu Jiang, Xinyan Wang, Juan Lyv","doi":"10.1080/14737140.2025.2465903","DOIUrl":"10.1080/14737140.2025.2465903","url":null,"abstract":"Research design and methods: Data were obtained from the SEER database for women diagnosed with EOC between 2004 and 2020. Clinical features, treatment regimens and overall survival (OS) were analyzed. Cox regression was conducted to identify prognostic factors associated with EOC. We employed 5-fold cross-validation to improve the accuracy of the model. Random Survival Forest (RSF), Gradient Boosting Survival Analysis (GBSA) and Support Vector Machine (SVM) were used to develop ML models, then compared with the Cox model. The predictive performance of these models was assessed using AUC, concordance index (C-index), and Brier scores.Results: A total of 12,949 EOC patients were selected from the SEER database. We identified 14 independent prognostic factors for OS and constructed predictive models. The GBSA model demonstrated superior AUC, C-index, and Brier scores across different time points, outperforming the Cox model. SHAP analysis showed that FIGO stage, grade, and lymph node dissection were the most important features in the GBSA model.Conclusions: The GBSA model outperforms traditional methods in survival prediction, offering a valuable tool for clinicians to make informed decisions about patient prognosis.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.9,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis. PD-L1抑制剂与PD-1抑制剂治疗肺癌的安全性：系统综述和网络荟萃分析

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-14 DOI: 10.1080/14737140.2025.2465901

Jianqiao Ding, Zheyu Liu, Jing Ning, Nan Sun

{"title":"Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis.","authors":"Jianqiao Ding, Zheyu Liu, Jing Ning, Nan Sun","doi":"10.1080/14737140.2025.2465901","DOIUrl":"10.1080/14737140.2025.2465901","url":null,"abstract":"Background: To explore the safety of PD-L1 inhibitors vs. PD-1 inhibitors in extensive-stage small-cell lung cancer (ES-SCLC) and non-small-cell lung cancer (NSCLC).Research design and methods: PubMed, EMBASE, and the Cochrane Library were searched up to 20 December 2023. Randomized controlled trials on patients with NSCLC/ES-SCLC treated with PD-1/PD-L1 inhibitor were included and synthesized with Bayesian network meta-analysis.Results: This meta-analysis included 58 studies. Regarding grade ≥3 treatment-related adverse events (TRAEs), PD-L1 inhibitors had better safety compared with PD-1 inhibitors when combined with chemotherapy in resectable NSCLC, presenting larger surface under the cumulative ranking (SUCRA) (0.577 vs. 0.168), similar with those in advanced NSCLC and ES-SCLC. The safety of PD-L1 inhibitors was better than PD-1 inhibitors regarding grade ≥3 pneumonia in resectable NSCLC when combined with chemotherapy (0.648 vs. 0.307), as well as in advanced NSCLC and ES-SCLC. When combined with chemotherapy, PD-L1 inhibitors had better safety regarding grade ≥3 pneumonitis, compared to PD-1 inhibitor (resectable NSCLC: 0.934 vs. 0.019; advanced NSCLC: 0.618 vs. 0.584; ES-SCLC: 0.505 vs 0.059).Conclusion: PD-L1 inhibitors might be a safer option than PD-1 inhibitors regarding grade ≥3 TRAEs and pneumonia, monotherapy or combined with chemotherapy, and when combined with chemotherapy regarding grade ≥3 pneumonitis.Registration: PROSPERO (CRD42024620372).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update understanding of stemness and chemoresistance of prostate cancer. 前列腺癌干细胞和化疗耐药的新认识。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-13 DOI: 10.1080/14737140.2025.2466680

Afiya Wahab, Hifzur R Siddique

{"title":"An update understanding of stemness and chemoresistance of prostate cancer.","authors":"Afiya Wahab, Hifzur R Siddique","doi":"10.1080/14737140.2025.2466680","DOIUrl":"10.1080/14737140.2025.2466680","url":null,"abstract":"Introduction: Globally, prostate cancer (CaP) is a leading cause of death and disability among men and a substantial public health burden. Despite advancements in cancer treatment, chemoresistance remains a significant issue in cancer therapy, accounting for the majority of patient relapses and poor survival. Cancer stem cells (CSCs) are considered the main cause of cancer recurrence, chemoresistance, and poor survival of patients. These CSCs acquire stemness and chemoresistance by certain mechanisms such as enhanced DNA repair processes, increased expression of drug efflux pumps, resistance to apoptosis, and altered cell cycle and tumor microenvironment (TME).Area covered: We cover the latest developments in this field and give an overview of future research directions.Expert opinion: CSCs show dysregulation of several signaling pathways, mostly related to conferring chemoresistance phenotype, such as high drug efflux, apoptotic resistance, quiescent cell cycle, tumor microenvironment, and DNA repair. There are several research articles published on this topic. However, still, this field warrants further investigations to identify the therapeutic molecule that can either chemosensitize CSCs or kill them effectively. This can only be possible when we know the complete mechanisms to comprehend the fundamental causes of cancer stemness and therapy resistance.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clarifications and comments on "infrared radiation for cancer hyperthermia: the light to brighten up oncology". 对“癌症热疗的红外辐射：照亮肿瘤的光”的澄清和评论。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-12 DOI: 10.1080/14737140.2025.2465890

A-M Lüchtenborg, P Vaupel, A R Thomsen, H Piazena

引用次数: 0

Disparities in consent to adjuvant radiotherapy in primary glioblastoma: a population-based study. 原发性胶质母细胞瘤患者对辅助放疗的同意差异：一项基于人群的研究。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-12 DOI: 10.1080/14737140.2025.2464935

Wang Miao, Liu Yang, Jinhu Li, Xia Yan, Ying Lu, Xin Yang

{"title":"Disparities in consent to adjuvant radiotherapy in primary glioblastoma: a population-based study.","authors":"Wang Miao, Liu Yang, Jinhu Li, Xia Yan, Ying Lu, Xin Yang","doi":"10.1080/14737140.2025.2464935","DOIUrl":"10.1080/14737140.2025.2464935","url":null,"abstract":"Background: Despite adjuvant external beam radiation therapy (EBRT) has long been the standard treatment for glioblastoma (GBM), a significant subset of patients chooses to refuse it. We aimed to investigate the factors influencing EBRT refusal in GBM.Research design and methods: Patients with GBM were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Both univariable and multivariable logistic regression analyses were employed to evaluate the adjusted odds ratios (aOR) for the refusal of EBRT in relation to various clinical and demographic characteristics.Results: Among the 29,994 patients analyzed, 675 (2.3%) opted to refuse adjuvant EBRT. Patients aged ≥ 55 years (55-64: aOR 1.63, 95% CI 1.04-2.61, p = 0.03; 65-74: aOR 1.80, 95% CI 1.17-2.87, p = 0.009; 75+: aOR 2.01, 95% CI 1.28-3.24, p = 0.002), being single (aOR 1.68, 95% CI 1.19-2.35, p = 0.002), with a household income of $55,000 to $64,999 (aOR 1.94, 95% CI 1.24-3.07, p = 0.004), and not undergoing chemotherapy (aOR 114, 95% CI 80.2-170.2, p < 0.001) had significantly higher odds of refusing adjuvant EBRT.Conclusions: This study underscores the necessity for targeted communication strategies by physicians regarding the benefits of adjuvant EBRT.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The discordance of biomarkers in primary tumour and synchronous axillary lymph node metastasis of the breast cancer, and its clinical significance in patients undergoing neoadjuvant therapy. 乳腺癌原发肿瘤与同步腋窝淋巴结转移生物标志物的不一致性及其在新辅助治疗患者中的临床意义

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-10 DOI: 10.1080/14737140.2025.2464199

Ali Kaan Sanal, Umit Turan, Ahmet Yugruk, Zeynel Abidin Taş, Oktay Irkorucu, Omer Taskin

{"title":"The discordance of biomarkers in primary tumour and synchronous axillary lymph node metastasis of the breast cancer, and its clinical significance in patients undergoing neoadjuvant therapy.","authors":"Ali Kaan Sanal, Umit Turan, Ahmet Yugruk, Zeynel Abidin Taş, Oktay Irkorucu, Omer Taskin","doi":"10.1080/14737140.2025.2464199","DOIUrl":"10.1080/14737140.2025.2464199","url":null,"abstract":"Background: This study explores the disparity in ER, PR, HER-2, and Ki-67 status between primary breast tumors (PBT) and axillary lymph node metastasis (ALNM) at initial admission in patients undergoing neoadjuvant chemotherapy (NAC).Research design and methods: Demographic-clinicopathological characteristics and histopathological response to NAC in both PBT and ALNM were recorded. Immunohistochemical analysis of ER, PR, HER-2, and Ki67 was performed separately in PBT and ALNM, with discordance rates compared. The disparity in biomarkers was assessed in relation to the histopathological response to NAC in both PBT and ALNM.Results: In 96 female patients, discordance rates between PBT and ALNM were 16.67% for ER, 16.67% for PR, 20.83% for HER-2, and 15.63% for Ki-67. Statistically significant differences in ER and PR discordance between PBT and ALNM were observed. Additionally, a significant difference in histopathological response to NAC was noted based on ER discordance.Conclusion: Precise assessment of ER and HER-2 status in axillary lymph node biopsy specimens is crucial in breast cancer patients with ALNM, potentially optimizing systemic and surgical treatment selection.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0